Advertisement
U.S. markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5652-0.0508 (-8.25%)
At close: 03:59PM EST
0.5697 +0.00 (+0.80%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.6150
Open0.6196
Bid0.5664 x 800
Ask0.5699 x 2200
Day's Range0.5478 - 0.6196
52 Week Range0.2570 - 9.2000
Volume555,608
Avg. Volume2,361,660
Market Cap16.788M
Beta (5Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-8.0000
Earnings DateMar 04, 2024 - Mar 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est760.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RDHL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Redhill Biopharma Ltd.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    10 months agoMorningstar
View more
  • PR Newswire

    RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a new publication of data from multiple experiments in the International Journal of Molecular Sciences1. The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradia

  • PR Newswire

    RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

    RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 10,000,00

  • PR Newswire

    RedHill Biopharma Announces $8 Million Registered Direct Offering

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS, in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregis